Skip to main content

Network pharmacology: a bright guiding light on the way to explore the personalized precise medication of traditional Chinese medicine

Abstract

Network pharmacology can ascertain the therapeutic mechanism of drugs for treating diseases at the level of biological targets and pathways. The effective mechanism study of traditional Chinese medicine (TCM) characterized by multi-component, multi-targeted, and integrative efficacy, perfectly corresponds to the application of network pharmacology. Currently, network pharmacology has been widely utilized to clarify the mechanism of the physiological activity of TCM. In this review, we comprehensively summarize the application of network pharmacology in TCM to reveal its potential of verifying the phenotype and underlying causes of diseases, realizing the personalized and accurate application of TCM. We searched the literature using “TCM network pharmacology” and “network pharmacology” as keywords from Web of Science, PubMed, Google Scholar, as well as Chinese National Knowledge Infrastructure in the last decade. The origins, development, and application of network pharmacology are closely correlated with the study of TCM which has been applied in China for thousands of years. Network pharmacology and TCM have the same core idea and promote each other. A well-defined research strategy for network pharmacology has been utilized in several aspects of TCM research, including the elucidation of the biological basis of diseases and syndromes, the prediction of TCM targets, the screening of TCM active compounds, and the decipherment of mechanisms of TCM in treating diseases. However, several factors limit its application, such as the selection of databases and algorithms, the unstable quality of the research results, and the lack of standardization. This review aims to provide references and ideas for the research of TCM and to encourage the personalized and precise use of Chinese medicine.

Introduction

The “one drug–one target–one disease” model is widely recognized as the paradigm in developing new medicines, which simplifies the screening of compounds and reduces the unwanted side effects of medication [1,2,3]. Highly selective therapeutic drugs against a single target have been shown to have limited efficacy and therapeutic effects, particularly for complex multifactorial diseases whose pathogenesis are modulated by diverse biological processes and various molecular functions [4]. It is obvious that the path of modulating multiple biological processes by designing highly selective compounds alone is not viable. In fact, in the past few decades, a constant reduction in the overall success rate of the development of clinical intervention agents has been observed [5]. Due to the complex signaling networks of diseases, multi-target and combinatorial drug therapy provide a new network-based approach to drug discovery [6]. Networks not only improve the therapeutic efficacy of drugs while predicting unwanted side effects but also provide a broader choice of disease targets, which revolutionizes the definition and treatment of diseases. With an increased understanding of the underlying therapeutic mechanisms of approved drugs on the market, it is demonstrated that many drugs with definite efficacy do not act on only one target, but frequently on multiple targets, such as anti-epileptic drugs Felbamate and Topiramate [7]. In addition, taking advantage of independent action targets and complementary mechanisms of action with more therapeutic benefit and less toxicity and resistance, the combination treatment is superior to monotherapy [8,9,10,11], as shown in the fixed combination of Vildagliptin/Metformin in type 2 diabetic patients [12]. The network pharmacology paradigm provides a bioinformatics network that demonstrates multiple disease genes and drug target genes are interconnected, thereby illustrating the drug-disease interactions and guiding the development and application of innovative drugs.

Meanwhile, the development of traditional Chinese medicine (TCM) has long been challenged and shackled by the modern “one drug–one target–one disease” dogma. Due to the complexity of compounds in TCM and the multi-targeted mechanism, the principle of drug development of TCM is moving away from clarifying holistic theory towards screening highly selective compounds from herbal medicines. However, this approach does not take into account the holistic and integrative efficacy of herbs. It is estimated that approximately one-third of approved drugs are derived from natural products and their derivatives [13]. The screened active compounds cannot reveal the integrative efficacy of herbal medicines and control their quality. Fortunately, in the form of compound preparations, TCM has been recommended and approved for effectively preventing and treating COVID-19 in China [14], and this natural model of combination therapy can revolutionize drug development. The rich TCM theory may facilitate the decipherment of the molecular mechanisms of drug combinations, enabling the clinical intervention of diseases according to their manifestation and root cause. Network pharmacology provides the possibility for the personalized precise medication of TCM by deciphering its efficacy through the scientific method. The review introduces the initial origin and subsequent development of network pharmacology, as well as its applications in the research fields of the precision treatment of TCM, to hopefully provide ideas and references for the personalized and precise use of traditional Chinese medicine.

The development history of network pharmacology

The origin of network pharmacology can be traced back to 1999 when Shao Li pioneered the “Syndrome” of a link between TCM and biomolecular networks at the first annual academic conference of the Chinese Association for Science and Technology [15]. A few years later, he suggested that the disease gene network might be regulated by the “multi-causal and micro-effective” effects of herbal formulae [16]. In 2007, Li et al. used bioinformatics to construct the first biomolecular network of Cold /Hot syndrome in TCM and found the network regulatory effects of the formulae for Cold /Hot syndrome [17]. In the same year, “Network Pharmacology” was introduced by Andrew L. Hopkins, a pharmacologist at Dundee University in the UK [1]. Figure 1A shows the development history of network pharmacology. Subsequently, network pharmacology has increasingly become a hot topic in pharmaceutical research. The search of the Chinese National Knowledge Infrastructure (CNKI) databases and Web of Science (WOS) showed that the number of articles about network pharmacology has increased dramatically in recent years (Fig. 1B, C). In particular, it has gained momentum in recent years and is expected to become a promising paradigm for the new generation of drug development [18]. In 2009, Pan Jiahu established a new model for drug discovery by using network pharmacology [19]. More recently, it has become a popular research topic in systematic pharmacological research, especially in the field of research on the pharmacodynamic mechanism of TCM, due to the high degree of overlap between the main ideas of network pharmacology and those of TCM. Next, Li established a “phenotypic network-biological network-Chinese medicine network” model for TCM evidence and TCM prescription research in the same year [20]. He proposed the idea of “network targets” for the first time two years later [21] and created a collaborative algorithm for predicting drug combinations through network targets. In 2021, to increase the credibility of results and standardize the feasibility of data, Li’s team developed and published the first international standard for network pharmacology “Guidelines for Evaluation Methods in Network Pharmacology” [22].

Fig. 1
figure 1

The timeline of major milestones for the development history of network pharmacology A. The number of papers published in the field of network pharmacology in CNKI B and WOS C. Reproduced from Ref [1, 3, 17, 23, 24]

Network pharmacology bumps into TCM

The origins and development of network pharmacology are tightly correlated with the study of TCM. Network pharmacology is a unique system established on the medical knowledge of traditional experience [25] and is fundamentally different from the “drug-target-disease” theoretical system of modern medicine [26]. TCM experience emphasizes the ideas of “diagnosis and treatment” and “holistic view” in the treatment of diseases, providing a natural model to study combination therapy. Specifically, Chinese herbs are usually in compounded preparations to form TCM formulas following the TCM principles of “the seven methods in prescription compatibility” and “Jun Chen Zuo Shi” as the combined therapy. In recent years, TCM has gradually stepped into the international arena, and the modernization of TCM has become the core issue of TCM research, which needs scientific validity. However, because of the complex of TCM ingredients and their complicated interactions with biological systems, the molecular mechanisms of TCM components are difficult to elucidate. Revealing the molecular mechanism and bioactive markers of TCM, as well as its toxic mechanism are urgent problems to be solved in the standardization of TCM [27]. TCM treatment is a multi-compound, multi-targeted, and integrative paradigm, while network pharmacology is a systematic biology method for the analysis of multi-target and multi-pathway pharmacological effects. Thus, network pharmacology has become a common strategy for investigating the therapeutic mechanisms of TCM, which is proved useful for deciphering the scientific basis of TCM. Through network pharmacology approach, some good preliminary achievement have been obtained in exploring the essential characteristics of TCM, discovering the multiple effects of TCM with multiple pathways, multiple targets, and multiple components [21, 27,28,29]. Collectively, network pharmacology and TCM have same core idea and promote each other.

Research strategies and application of network pharmacology

According to previous studies [30,31,32,33,34], a comprehensive search of Web of Science, PubMed, Google Scholar, as well as Chinese National Knowledge Infrastructure in the last decade was performed in this study. Using specific keywords related to “TCM network pharmacology” or “network pharmacology”, relevant articles including in silico, in-vitro or animal experiments and review articles were identified. Inclusion criteria: these selected articles were assessed and categorized for information about the databases for network pharmacology, network visualization and analysis, and the application of network pharmacology in TCM including elucidating the biological basis of diseases and syndromes, predicting the targets of TCM, screening bioactive substances, deciphering mechanisms. Exclusion criteria: articles uncovering the current issue and those with incomplete information, letter to the editor, and short communications. The research strategies and current application of network pharmacology in the field of TCM are comprehensive overviewed, offering guidance for utilizing network pharmacology to uncover the modern scientific essence of TCM based on previous work [35,36,37].

Research strategies of network pharmacology

We firstly presented the research steps involved in network pharmacology. The procedures of network pharmacology focus on the following steps: (1) mapping the disease phenotypic targets and the drug targets together in the biomolecular network; (2) establishing the mechanism of association between diseases and drugs; (3) analyzing the network to dissect the mechanism between network targets and the system regulation. Network targets are the key ideas of network pharmacology [38, 39], which assumes that disease phenotypes and drugs act on the same network, same pathway, or even the same target, thus affecting the balance of network targets and interfering with the phenotype at all levels. Therefore, we summarized network pharmacology-related databases and strategy for network visualization and analysis.

Databases for network pharmacology

The model of network pharmacology is constructed by the collection which is based on screening of information on bioactive components, target genes, and disease genes in various databases. Many scholars and experts have developed databases related to network pharmacology, which integrate relevant information in the field of medicine and provide a basis for research in network pharmacology [40]. These databases are divided into several categories, including herb/compound databases, disease databases, and gene/protein databases. Commonly used databases for network pharmacology research involve TCMSP (http://sm.nwsuaf.edu.cn/lsp/tcmsp.php) [41], HERB(http://herb.ac.cn/) [42], TCMBank(https://www.tcmbank.com/) [43], HIT(http://lifecenter.sgst.cn/hit/) [44], ETCM (http://www.nrc.ac.cn:9090/ETCM/) [45], TCMID (http: //www.megabionet.org/tcm-id/) [46], CMAUP(CMAUP—Collective Molecular Activities of Useful Plants (bidd.group)) [47], YaTCM(http://cadd.pharmacy.nankai.edu.cn/yatcm/home) [48], TCM database@Taiwan (http://tcm.cmu.edu.tw) [49], Pubchem (https://pubchem.ncbi.nlm.nih.gov) [50], STRING (https://string-db.org) [51], Uniprot (https: //www.uniprot.org/) [52], Drugbank (www.drugb-ank.ca) [53], OMIM (https://www.omim.org/) [54], GeneCards (www.genecards.org) [55], DisGeNET (https://www.disgenet.org/api) [56], TTD (https://idrblab.org/ttd/) [57], DAVID (https://david.ncifcrf.gov) [58], Metascape (http://metascape.org) [59], and KEGG (https://www.kegg.jp/) [60] (Table 1).

Table 1 Databases related to network pharmacology

Network visualization and analysis

In network pharmacology, a network is defined as the linking of targets, compounds, signaling pathways, and other elements in a specific way, forming a network diagram of interactions. Network visualization is about extracting interaction information from linked data and using tools to visualize and analyze [61]. Depending on the kind of nodes, networks can be grouped into 2 main types: single-element networks whose nodes represent the same type of element (such as protein–protein interaction networks) (Fig. 2A) and multi-element networks whose nodes contain multiple types of elements (such as drug-target-disease networks and drug-target-pathway networks) (Fig. 2B). The difference in network properties not only affects the visualization of the final result but also offers the choice of method for network analysis and the topology of the network academic properties [62].

Fig. 2
figure 2

The network of different categories. Protein–protein interaction networks whose nodes are protein (A). Compound-target-signaling pathway networks are composed of compound nodes, protein nodes, and signaling pathway nodes (B)

There are two steps in network visualization: (1) the addition of network nodes, the establishment of links between them, and the assignment of attributes to them; (2) the description of the network and the extraction of abundant instruments to characterize the framework feature that visibly stands for the network [61]. Network pharmacology visualization is often achieved through professional software such as Cytoscape. Jian Yang [63] constructed a visual network of eight prescriptions and herbs and analyzed the network to classify the eight prescriptions into five categories, which showed the similitude of the category of the prescription at the herb level. The network analysis is used to capture useful information in the network by extracting targets and drugs to obtain key targets, active compounds, and metabolic pathways. Several approaches are employed for network analysis, typically involving network structure analysis, network function analysis, and network analogy analysis [64].

The application of network pharmacology in TCM

Network pharmacology research strategies are clear and easy to apply, so they have been used in many directions of TCM research. Network pharmacology offers an opportunity that shifts the research strategy of TCM prescriptions from empirical to evidence-based research. With the utilization of network pharmacology, many aspects of TCM research have been studied and many research results are available [35,36,37, 65, 66]. The research ideas of the network pharmacology strategy in TCM research are displayed in Fig. 3. This section summarizes the utilization of network pharmacology to TCM in four main areas: elucidating the biological basis of diseases and syndromes, predicting targets for TCM, screening for bioactive substances, and deciphering mechanisms.

Fig. 3
figure 3

Schematic diagram of the utilization strategy of network pharmacology in TCM research

Elucidating the biological basis of diseases and syndromes

It is challenging to clarify the biological basis of syndromes and diseases because of the complicated philosophy of Chinese medicine and the unclear pathophysiology of diseases. Network pharmacology offers opportunities to systematically reveal the causal mechanisms through biomarkers of disease or syndrome by combing with multi-omics. Network pharmacology is not only dependent on the data collection but also on the algorithmic scores. Algorithms have also been developed for cancer drug sensitivity calculation and cancer biomarker screening. Ali Oskooei et al. [67] have used a new algorithm called network-based bias tree ensembles which are utilized in the calculation of cancer drug sensitivity and the decipherment of agent sensitivity biomarkers. The network-based bias tree ensembles algorithm is more reliable in predicting IC50 drug sensitivity than the unbiased randomized forests algorithms which is only applicable to the targeted membrane receptor pathway. Based on their findings, they proposed that for agents that down-regulate the targeted membrane receptor pathway, the levels of targeted genes before administration are the biomarkers of IC50 drug sensitivity [67].

Network pharmacology combined with multi-omics has been employed to screen the biomarkers of different diseases for clarifying the biological basis of diseases and TCM treatment. Zhang et al. [68] employed a comprehensive strategy based on metabolomics and network pharmacology for the accurate screening of diagnostic biomarkers. They explored the diagnostic biomarkers through systems pharmacology and metabolomics-based techniques and developed a viable pharmacological model. They used this model to identify 23 biomarkers for the treatment of acute ulcerative colitis with Pulsatilla chinensis (Bge.) Regel decoction (PD). Fang Sheng-Quan [69] combined network pharmacology with transcriptional profiling approaches to analyze and identify biomarkers for the in vivo treatment of gastric cancer with the Huosu Yangwei Formula. Dong et al. [70] identified 18 potential biomarkers that are associated with insomnia and mood disorders and found that the metabolic markers were altered in mice intervened with Sedum L. using metabolomic technique and network pharmacology approaches. Wang et al. [71] investigated the pharmacodynamic components and bioactive mechanisms of Dendrobium chrysostom Lindl. in treating precancerous lesions of gastric cancer via network pharmacology. The results suggested a possible therapeutic effect by modulating the HRAS-PI3K-AKT pathway. Acute myeloblastic leukemia is a type of malignant disease, that originates from the malignancy of stem cells, and patients with this acute myeloblastic leukemia have a high risk of death. Yuan et al. used a non-targeted metabolomic technique and network pharmacology-based strategy to decipher its pathogenesis, identifying 75 biomarker targets [72]. Sun et al. explored the common biomarkers of coronary heart disease and hyperlipidemia by integrating lipidomic techniques and network pharmacology [73]. Using network pharmacology and lipidomics strategy, berberine was demonstrated to regulate glycerophospholipid and sphingolipid metabolism for treating hyperlipidemia, and 13 metabolites were discovered as biomarkers of berberine regulation [74].

The advanced detection technology combined with network pharmacology method to explore biomarkers of diseases and symptoms is a new approach to pharmaceutical research. The combined use of network pharmacology and metabolomics is favored by some academics. This approach identified 5 key biomarkers of peonidin against cholestatic liver injury [75], 20 potential biomarkers and 10 major pathways of immune regulation of macrophages by ginseng [76], and 21 biomarkers of type 2 diabetes [77]. The metabolomics analysis identified phosphatidylcholine and phosphatidylethanolamine as biomarkers of Long Chai Fang against duck hepatitis B virus [78]. The research suggested that TNF-α, iNOS, MAPK3, eNOS, mTOR, and COX2 are implicated in the immune and inflammatory responses caused by psoriasis [79]. Network pharmacology was utilized to decode the associations between metabolic biomarkers and depression, and 9 metabolite targets correlated with the neurological, immune, and endocrine systems are potential drug targets for the treatment of depression, including PTEN, TP53, HLA-DRB1, bIL1B, TNF, HRAS, MTOR, PIK3CA, and INS [80]. It was demonstrated that Qi-Fu-Yin had a modulating effect on iNOS, a neuroinflammatory biomarker of Alzheimer's disease, as verified by online pharmacological analysis and experiments [81]. Another research has revealed that MMP9, QPCT, and CA1 were potential bioactive markers for patients with nonunion and targets for Dipsacus asper Wall.ex Henry [82]. In summary, the network pharmacology approach has been proved useful in identifying active ingredients and elucidating the material basis and mechanisms of biomarkers.

Predicting the targets of TCM

The traditional technique for identifying the drug target is to use small molecules as probes, and the biochemical methods study the expression of relevant proteins or the specific binding of small molecules to protein macromolecules to locate the specific binding sites. The identification of agent targets has become a hot study field in Chinese herbal preparations, and drug target discovery is a critical progress in drug research [83]. Network pharmacology is a comprehensive method combining computer-aided algorithms and virtual models to predict multi-target, which is widely employed for the identification of new targets for complicated TCM formulas. Guo et al. [84] used the network-based pharmacological strategy to discovery the major targets for the anti-inflammatory activities of Lonicera japonica Thunb (honeysuckle)using the network pharmacology method and validated its effects by the molecular docking and ex vivo verification experiments. The results demonstrated that honeysuckle can significantly down-regulate the levels of AKT and TNF-α in RAW264.7 cells. Other scholars have predicted the anti-inflammatory mechanisms of different drugs. The main targets predicted for the anti-inflammatory action of Lantana camara L. were IL2, RELA, PRKCA, FOS, and MAPK 14 [85]. Han et al. [86] employed experimental validation and network pharmacology to identify the targets of Curculigoside A in rheumatoid arthritis and osteoporosis. Tao et al. [87] analyzed the molecular targets of the Huashi Baidu formula for the medical Intervention of COVID-19 via integrating molecular docking validation with network pharmacology.

The development of agents for treating cancer is now becoming a major hot topic, and TCM for cancer has received a lot of interest from researchers, with most of the relevant studies already available. However, the traditional methods of mechanism research of TCM for cancer treatment can only reveal limited targets. With the development and promotion of network pharmacology, it is possible to effectively reveal potential targets. Through the application of network pharmacological and in vitro experiments, it was showed that Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) Hsiao (Huangqi) promotes apoptosis in colorectal cancer cells by reducing the levels of CXCL10, PTGS2, CXCL8, and CCL2 genes [88]. Besides, it was suggested that AKT1, JUN, CDKN1A, BCL2L1, and NCOA1 are the major targets for Zuojinwan in the therapy of colorectal cancer [89]. Lan et al. [90] explored the main targets of Rheum palmatum L. for cancer treatment, and their results indicated that targets such as JUN, CASP3, TNF, MYC, and PTGS2 were involved in the anti-tumor treatment of Rheum palmatum L. (Rhubarb). The results from triple-negative breast cancer studies have shown that Curcumin and its nano-formulations down-regulated the expression levels of 10 key genes, including TNF, STAT3, PTGS2, AKT1, EGFR, MMP9, PPARG, NFE2L2, GSK3B, and EP300 [91]. In Qingli Cui's research, 23 targets were revealed for ginseng extracts for treating gastric cancer [92]. Gong et al. [93] successfully predicted the bioactive compounds and main targets of Codonopsis pilosula (Franch.) Nannf against Osteosarcoma, with TP53, HSP90AA1, CCND1, and AR playing a significant role in the clinical intervention. The network pharmacology approach is well applied in the prediction of cancer targets for Chinese medicine treatment.

In addition, network pharmacology is used in the treatment of other pathological disorders via Chinese medicine. Specifically, it was applied to the prediction of potential targets for Acteoside therapy [94], identification of targets of Salvia miltiorrhiza Bge. against Oral Submucous Fibrosis [95], and investigation of the key target of Rhamnocitrin against Oxaliplatin-induced neuropathic pain [96]. Besides, several researchers have predicted the therapeutic targets for diabetes and diabetic nephropathy, including TNF, TP53, PTGS2, MAPK1, AKT1, IL-6, JUN, and MMP9 [97,98,99,100]. Chen et al. [101] utilized a network pharmacology method to identify MAPK1, MMP9, NFKBIA, and other targets that were involved in the treatment of myocardial infarction with Suxiao xintong by dropping pills. Network pharmacology has also been used to explore key targets for the treatment of allergic rhinitis with Tuomin-Zhiti-Decoction [102], the exploration of potential targets for immuno-inflammatory in patients with ankylosing spondylitis [103], and the clarification of targets for Aidi injection for treating pancreatic cancer [104]. Based on network pharmacology, Beihui He et al. revealed that JUN, PTGS2, CDKN1A, and MYC were the targets of Shenqi Pill for treating non-alcoholic steatohepatitis via network pharmacology. In another study, VEGF-C was predicted as an important target of flavonoids from Citrus × limon (Linnaeus) Osbeck against non-alcoholic steatohepatitis through network pharmacology [105, 106]. Through network pharmacology, it was indicated that the hepatoprotective effects of Salvia miltiorrhiza Bge. were tightly correlated with the modulation of intracellular PPARα, CYP1A2, and MMP2 [107].

Screening bioactive substances

The lack of clarity of effective substances in Chinese herbal formulas is one of the critical problems causing the bottleneck in the research of Chinese herbal formulas. Hence, there is an urgent need for an integrated approach that can identify multiple bioactive compounds [108]. Network pharmacology provides a simple way to map the potentially effective components into the disease gene networks to find the pharmacodynamic substances. For instance, KiKwangOh et al. [109] employed a network pharmacology approach to identify the bioactive substances associated with diabetes in Sorghum bicolor (L.) Moench, ultimately identifying four bioactive substances associated with diabetes. Zhang et al. [110] identified 6 bioactive components of ginger for colon cancer prevention through an integrated network pharmacological approach. Man Kit Cheung and Li Han have studied separately active ingredients of Andrographis paniculata (Burm. f.) Nee in esophageal cancer treatment and anti-gastric-cancer effect of herbal Sarcandra glabra (Thunb.) Nakai. The former identified a total of 22 potential therapeutic ingredients for esophageal cancer [111], while the latter identified a total of 6 active ingredients against gastric cancer [112]. In the study of the antidepressant component of Rehjnannia glutinosa Libosch., the main active ingredients included melittoside, catalpol, gardoside, genameside C, genipin-1-gentiobioside, and 6-O-p-coumaroyl ajugol [113]. Network pharmacological studies showed that the antibacterial bioactive substances of Paeonia rockii (S. G. Haw & Lauener) T. Hong & J. J. Li were flavonoids and phenolic acids [114]. In addition, 12 active ingredients in Polygonum cuspidatum Sieb. et Zucc. (Polygonum) was able to relieve asthma symptoms [115]. From the collagen hydrolysates of Andrias davidianus skin, a peptide named GPPGPA was identified through network pharmacology [116].

Different scholars have studied the anti-inflammatory active ingredients of Pudilan Xiaoyan Oral Liquid and Ba-Wei-Long-Zuan Granule. There were 41 potential bioactive ingredients in Pudilan Xiaoyan Oral Liquid [117], and the most relevant active ingredients of Ba-Wei-Long-Zuan Granule for anti-inflammation were coclaurine and hesperidin [118]. It has also been shown that Huangtu Decoction was able to treat colitis with wogonin considered to be the most effective bioactive substance [119]. Wang et al. [120] combined the phytochemical and network pharmacological approaches to identify the bioactive substances and the underlying mechanism of the drug for treating precancerous lesions in the stomach and validated 13 bioactive substances. Besides, 25S-macrostemonoside P was believed to be the bioactive substance of Gualou Xiebai Decoction in alleviating coronary heart disease [121]. Meanwhile, network pharmacology and molecular docking technologies were applied to identify the bioactive substances of Cuscuta australis R. Br. (Cuscutae Semen) in the therapy of Osteoporosis [122], revealing the basis of biological activity of Xuanbai Chengqi decoction for treating COVID-19 [123], and discover the pharmacodynamic compounds of Cuscutae Semen-Morus alba L. coupled-herbs in treating Oligoasthenozoospermia [124].

The quality of herbs is also an important factor in ensuring efficacy. The introduction of Q-markers has established a value framework for quality control in Chinese medicine [125], and the use of network pharmacology methods to screen herbal quality markers has been accepted by many researchers. Cao et al. predicted the quality markers of Cistanche deserticola Y. C. Ma. (Cistanches Herba), and their results preliminarily confirmed echinacoside, acteoside, isoacteoside, cistan oside F, 2′⁃acetylacteoside, cistanoside, and ferulic acid as quality markers for Cistanches Herba [126]. Chen et al. determined 6 flavonoids as the quality markers for Sophora flavescens Ait. [127]. Duan et al. screened the quality markers of Wuji Baifeng Pills which include ferulic acid, formononetin, senkyunolide A isoliquiritigenin, and neocryptotanshinone [128]. Network pharmacology coupled with multiple different techniques has been widely utilized to screen Q-markers of Da-Cheng-Qi decoction [129], Periplocae Cortex Bge. [130], Alisma orientale (Sam.) Juzep. [131], Trifolium pretense. L [132], Baizhu dispensing granules [133], and Xinjiang Cydonia oblonga Mill. for antiatherosclerosis [134]. Lan et al. [135] analyzed the quality markers of Rheum palmatum L. in Fengyin Decoction through fingerprinting and network pharmacology and tentatively identified compounds such as Rhubarb anthraquinone as the potential quality marker. Network pharmacology-metabolomics-PK/PD modeling was used to screen quality markers for the therapy of acute lung injury with Qingzao Jiufei decoction [136], a total of 9 representative components were extracted from the 15 active compounds as the quality markers.

Deciphering mechanisms

The clinical medication characteristics of TCM are multiple components, targets, and signaling pathways of action, making it hard to clarify the underlying mechanism with the traditional methods. With the rise and popularity of network pharmacology, it has become an effective approach to utilize network pharmacology to discover the pharmacodynamic substances and active mechanisms of TCM [23]. Deng et al. [137] utilized the network pharmacology strategy to decipher the pharmacodynamic compounds and the molecular mechanisms of the anti-inflammatory and antiviral effects of Isatis indigotica Fortune and its mechanism of action. The findings suggested that the indoles, lignans, and flavonoids of Isatis indigotica Fortune exert anti-inflammatory and antiviral efficacy through suppressing IL-1β and TNF-α expression and regulating the immune system and PI3K-Akt signal pathway. Cui et al. elucidated that the anti-inflammatory pharmacological activity of tanshinone I and cryptotanshinone, components of Salvia miltiorrhiza, relates to the down-regulation of TLR signaling pathway and the regulation of iNOS synthesis [138]. Zhang et al. [139] investigated the molecular mechanisms of Salvia miltiorrhiza for treating diabetic nephropathy by combining the molecular docking and network pharmacology methods. The results of molecular docking demonstrated that tumor necrosis factors, NOS2 and AKT1, the targets of diabetic nephropathy, had higher binding to salvianolic acid B than salvianolic acid A. Other researchers have deciphered the mechanisms of different herbs in the therapy of diabetes and its complications, including Coptis chinensis Franch. (Coptidis) [140], Gegen Qinlian decoction [141], Silkworm excrement [142], Qingrekasen granule [143], and Yishen capsules [144]. Guo et al. [145] used a network pharmacology strategy to study the therapeutic mechanisms of TCM formula Zuojin Pill against hepatocellular carcinoma. Both in vitro and in vivo results suggested that Zuojin Pill regulates cell proliferation by modulating the expression of EGFR/MAPK, PI3K/NF-κB, and CCND1, showing significant therapeutic effects in hepatocellular carcinoma.

Several researchers have studied the active mechanism of different herbs for the treatment of the same disease. Although the pharmacological mechanisms of different herbs are not the same, the TCM theory expressed as “the same disease with different treatments” can be elucidated using network pharmacology. The efficacy of Hydroxysafflor yellow A against ischemic stroke is mediated through related to the control of oxidative stress and cellular and vascular renewal [146]. Besides, another experimental validation revealed the pharmacologic action of luteolin on ischemic stroke via the TNF signaling pathway [147]. Cui et al. and Fan et al. investigated the cardioprotective and angiogenesis mechanisms of different herbal medicines for treating myocardial infarction [148].

In addition, network pharmacology has also been carried out to explore the therapeutic mechanisms of many diseases including the treatment of recurrent respiratory infections with improved Panax ginseng C. A. Mey (Ginseng)-Schisandra [149], Nauclea officinalis against LPS-induced acute lung injury [150], Coptis chinensis treat Kawasaki disease [151], and Astragalus complanatus R. Br. anti-aging [152]. The mechanism of action of Shenling Baizhu powder on pyrotinib-induced diarrhea the therapeutic mechanisms of Astragalus mongholicus Bunge in non-alcoholic steatohepatitis, and the anti-Hashimoto thyroiditis effect of Prunella vulgaris L. were all the result of multiple signaling pathways acting together [153,154,155]. Besides, Bos taurus domesticus Gmelin effectively protected neurovascular units in the brain through HIF-1α, PI3K/Akt, and VEGF signaling, thereby affecting the development of ischemic stroke [156]. In the study of arthritis, total flavonoids of Drynaria fortunei (Kunze) J. Sm. in the drug intervention of rheumatoid arthritis involved in multiple signaling pathways, particularly closely linked to the inhibition of Th17 differentiation and synovial cell inflammatory responses [157]. The application of Aconiitum carmichaelii Debx.-Cinnamomum cassia Presl for treating osteoarthritis was largely associated with apoptosis and mitochondrial functional metabolism, which inhibited chondrocyte degeneration by inhibiting the protein and mRNA levels of chondrocyte caspase-3 and promoting the synthesis of ATP [158]. Chen et al. [159] predicted that the underlying mechanisms of Angong Niuhuang Pills for treating neoplastic pneumonia was related to the compound binds to multiple targets which in turn participate in the JAK-STAT and MAPK signaling pathways, thus exerting a therapeutic effect. It was revealed that Curcuma aromatica Salisb. significantly improved blood stasis, myocardial infarction, and lipid levels through regulation of the PI3K/AKT/mTOR signaling pathway in rats with coronary artery disease [160]. Network pharmacology and the experimental validation have shown that Polygonum-Ligustrum lucidum Ait. acted as a therapeutic agent for acute gouty arthritis by modulating IL-1β,TNF-α, and IL-6 targets [161]. The above studies showed that the combination of molecular docking, network pharmacology, and experimental validation could elucidate the therapeutic mechanisms of TCM for preventing and treating diseases, which was a simple and practical approach. A various of methods include pharmacokinetics, molecular docking, different omics techniques, as well as pharmacology experiments have been widely employed to decipher the mechanism of action of TCM by integrating with network pharmacology (Table 2).

Table 2 Deciphering mechanism of action of TCM using network pharmacology

Network pharmacology as the opportunity for the personalized precise medication of TCM

Diseases are abnormal processes of the bodily activity triggered by a disruption in the self-regulation of body under the influence of certain factors, resulting in an associated disease phenotype. Because of the complicated network of human diseases and the incomplete understanding of the causes of diseases, diseases are always clarified by symptoms manifesting in organs. Thus, diseases are mainly treated by curing the symptoms, but not the cause. Currently, scientists have started to realize that the development of a disease can be described as the dysregulation of one or more interacting network processes, as described by Nogales [24] (Fig. 4A). Network pharmacology is a research strategy that focuses on “network targets”. As a result, it is a reasonable approach to characterize both the manifestation and the root cause of diseases by taking advantage of integrated and systematic biology approaches, such as epigenomics, transcriptomics, proteomics, and metabolomics [167, 168]. Disease phenotypes should be categorized by the dysregulation of biological networks rather than mechanistically unrelated proteins (Fig. 4B). Network pharmacology has been a promising method for advancing drug discovery and illuminating the underlying mechanism of multi-targeted compounds [169,170,171]. It presents diseases as perturbations of intertwined molecular networks and characterizes the therapeutic mechanisms of drugs through the network topology. TCM exerts its therapeutic effect through regulating biological networks, and the potential mechanism of TCM can be explained by using network pharmacology [25]. With the rapid growth of systematic biology and bioinformatic technologies, the network pharmacology is developing rapidly. Network pharmacology provides an opportunity for precisely treating diseases by clarifying both the symptoms and causal mechanisms, enabling personalized precise medication of TCM. The “Evidence-based Precision Medicine in TCM” integrates the evidence-based theory of TCM diseases and the integrated biological data research knowledge network uses the evidence as a benchmark for the comprehensive classification of patients and provides a more precise treatment under the guidance of evidence-based medicine [172]. With the progress of TCM syndrome, the evidence can be initially classified by modern means based on gene expression, which can relatively reduce the dialectical reliance on TCM practitioners. The network pharmacology can decipher the corresponding biomarkers of the syndrome and the mechanisms of drug-drug interactions, providing plenty of effective evidence which can then be used in large-scale clinical trials and employed to verify the efficacy. This will enable the integration of dialectical thinking and evidence-based precision medicine in TCM, realizing personalized precise medication of TCM [83]. Network pharmacology opens up opportunities for the personalized and precise use of TCM by establishing a link between TCM and biological networks at the molecular level. It is essential to explore how network pharmacology can be more scientifically integrated with the theory of Chinese medicine to promote the personalized precise medication of TCM.

Fig. 4
figure 4

Human disease networks and endotyping disease clusters. Human disease networks (A); endotyping disease clusters (B). Reproduced from Ref. [24]

Perspective

With its complex chemical composition and the ill-defined mechanisms of action, TCM has always been treated as an empirically based medicine, but the effectiveness of TCM is undeniable. The conventional “one target-one drug-one disease” research paradigm does not apply to TCM research, hence hindering the conduction of evidence-based study of TCM. Network pharmacology is undoubtedly an excellent adjunct to TCM research, because it connects the old idea of TCM and modern scientific practices. Herein, we summary the utilization of network pharmacology strategy in understanding the formulation of herbs, the therapeutic mechanisms of herbal medicines for treating diseases, the exploration of the potential targets, and identifying the pharmacodynamic material basis of herbal medicines for treating diseases. The hope is a major change in drug development and therapy which follows multiple components, multiple targeted, and multiple pathway manners. With the aging of the population in the East Asian TCM culture circle, the number of patients with multiple chronic diseases is increasing. In the course of long-term medication of TCM, the traditional medication scheme not only is ineluctable to cause the waste of drug resources, but also brings about unsatisfactory treatment effect treatment effects and irreversible damage to the body. Through the utilization of network pharmacology integrating systems biology, bioinformatics, and computer science, accurate prediction of individual complex pathological pathways and personalized prescription medication will be greatly developed. Network pharmacology is a bright guiding light on the way to explore the personalized precise medication of TCM.

Notably, several factors may limit the utilization of network pharmacology, such as the selection of databases and algorithms, the unstable quality of the research results, and the lack of standardization. The integrity of the database data and the rationality and credibility of the algorithms determine the verifiability and trustworthiness of the network pharmacology results. Among the various databases and algorithms, it is not at all clear which explains the mechanisms of drug combination well. For example, the selection of active compounds in herb medicines is often based on indicators of oral bioavailability and drug-like properties which may lack a solid foundation. Besides, the most commonly discussed disadvantage of this method is the reliability of the data interpretation, which depends highly on the database coverage. Fortunately, the development of Network Pharmacology Evaluation Method Guidance is a critical step for advancing the development of network pharmacology, which will help to promote the use of the new pharmaceutical research model in a more standardized and rigorous manner and stimulate the development of the new frontiers in the network pharmacology in TCM research [27, 173]. Additionally, the inability of network pharmacology to map complex interactions simultaneously limits the utility in clarifying the relationship among the compounds, gut microbiota, and the host. Finally, most of the network pharmacology methods only construct interaction networks between compounds and targets, losing concentration-related information. Thus, the screened components using network pharmacology may not be the best-acting compounds in herbal medicines because the therapeutic effects cannot be verified. The above-mentioned issues are the main problems and obstacles in the development of network pharmacy. In the era of rapid advances in information technology, there is an unstoppable trend toward the utilization of network pharmacology for the comprehensive and systematic research of TCM. In the future, the network pharmacology has to be constantly improved to ensure its sustainable development and application, for example, combining with other methods and techniques, enriching the content of the various databases, and updating the reliability. In addition, to make the results more convincing and representative, general standards should be set for the network pharmacology analysis methods. Network analysis methods should be improved to make it commonplace. It will also be important to quantify the active ingredient to determine whether it has reached the pharmacodynamic concentration. To prove its credibility, the network pharmacology results should be effectively combined with pharmacology, pharmacokinetics, toxicology, and pharmacodynamic related experiments. Collectively, network pharmacology offers a new opportunity for precisely treating both the manifestation and the root cause of disease.

Availability of data and materials

Not applicable.

Abbreviations

AKT:

Protein kinase B

AMPK:

Adenosine 5’-monophosphate (AMP)-activated protein kinase

AR:

Androgen Receptor

ATP:

Adenosine 5’-triphosphate

BCL2L1:

B-cell lymphoma-2 like 1

BIL1B:

Interleukin-1 beta

CA1:

Carbonic anhydrase 1

CAMP:

Cyclic Adenosine 5’-monophosphate

CASP3:

Caspase-3

CCL2:

Chemokine ligand 2

CCND1:

Cyclin D1

CDKN1A:

Cyclin dependent kinase inhibitor 1A

CMAUP:

Collective Molecular Activities of Useful Plants

CNKI:

Chinese National Knowledge Infrastructure

COVID-19:

Corona Virus Disease 2019

COX2:

Cyclooxygenase-2

CXCL10:

C-X-C motif chemokine ligand 10

CXCL8:

C-X-C motif chemokine ligand 8

CYP1A2:

Cytochrome P450 family 1 subfamily A member 2

DAVID:

The Database for Annotation Visualization and Integrated Discovery

DisGeNET:

Generate gene-disease networks

EGFR:

Epithelial growth factor receptor

ENOS:

Endothelial nitric oxide synthase

EP300:

E1A binding protein p300

ER:

Estrogen receptor

ETCM:

The Encyclopedia of Traditional Chinese Medicine

F10:

Coagulation factor X

F2:

Coagulation factor II

F7:

Coagulation factor VII

FOS:

Fos proto-oncogene

GRP78:

Glucose regulated protein 78 kD

GSK3B:

Glycogen synthase kinase 3β

HERB:

A high-throughput experiment and reference-guided database of traditional Chinese medicine

HIF-1α:

Hypoxia-inducible factor-1α

HIT:

Herbal Ingredients’ Targets Database

HLA-DRB1:

Major histocompatibility complex, class II, DR beta 1

HRAS:

HRas proto-oncogene

HSP90AA1:

Heat shock protein HSP 90-alpha

IL-17:

Interleukin 17

IL-2:

Interleukin 2

IL-6:

Interleukin 6

INOS:

Nitric oxide synthase

INS:

Insulin

JAK:

Janus kinase

JUN:

Jun proto-oncogene

KEGG:

Kyoto Encyclopedia of Genes and Genomes

MAPK:

Mitogen-activated protein kinase

MMP:

Matrix metalloproteinase

MTOR:

Mammalian target of rapamycin

MYC:

MYC proto-oncogene

NCOA1:

Nuclear Receptor Coactivator 1

NFE2L2:

Nuclear factor, erythroid 2 like 2

NFKBIA:

NFKB inhibitor alpha

NF-κB:

Nuclear factor-kappa B

NOS:

Nitric Oxide Synthase

OMIM:

Online Mendelian Inheritance in Man

PI3K:

Phosphatidylinositide 3-kinases

PIK3CA:

Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

PLAU:

Urokinase plasminogen activator

PPARG:

Peroxisome proliferator activated receptor gamma

PPARα:

Peroxisome proliferator activated receptor α

PPAR-γ:

Peroxisome proliferator activated receptor γ

PRKCA:

Protein kinase C alpha

PTEN:

Phosphatase and tensin homolog deleted on chromosome ten

PTGS2:

Prostaglandin-endoperoxide synthase 2

QPCT:

Glutaminyl-peptide cyclotransferase

RAW264.7cells:

Mouse Mononuclear Macrophage Leukemia Cells

RELA:

RELA proto-oncogene

RRTI:

Recurrent respiratory tract infection

STAT:

Signal transducer and activator of transcription

STAT3:

Signal transducer and activator of transcription 3

TCM:

Traditional Chinese Medicine

TCMID:

Traditional Chinese Medicines Integrated Database

TCMSP:

Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform

TLR:

Toll-like Receptor

TNF:

Tumor necrosis factor

TP53:

Tumor protein p53

TTD:

Therapeutic Target Database

UK:

United Kingdom

VEGF:

Vascular endothelial growth factor

WOS:

Web of Science

YATCM:

Yet another Traditional Chinese Medicine database

References

  1. Hopkins AL. Network pharmacology. Nat Biotechnol. 2007;25(10):1110–1.

    Article  CAS  PubMed  Google Scholar 

  2. Jiang W, Bao Y, Du G. Research progress of network chinese pharmacology. Inform Trad Chin Med. 2018;35:122–6.

    Google Scholar 

  3. Casas AI, Hassan AA, Larsen SJ, et al. From single drug targets to synergistic network pharmacology in ischemic stroke. Proc Natl Acad Sci USA. 2019;116(14):7129–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Makhoba XH, Viegas CJA-OX, Mosa RA-O, et al. Potential impact of the multi-target drug approach in the treatment of some complex diseases. Drug Des Devel Ther. 2020. https://doi.org/10.2147/DDDT.S257494.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Sun D, Gao W, Hu H, et al. Why 90% of clinical drug development fails and how to improve it? Acta Pharmaceutica Sinica B. 2022. https://doi.org/10.1016/j.apsb.2022.02.002.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Löscher W, Klein P. New approaches for developing multi-targeted drug combinations for disease modification of complex brain disorders. Does epilepsy prevention become a realistic goal? Pharmacol Ther. 2022;229:107934.

    Article  PubMed  Google Scholar 

  7. Löscher W. Single-Target versus multi-target drugs versus combinations of drugs with multiple targets: preclinical and clinical evidence for the treatment or prevention of epilepsy. Front Pharmacol. 2021. https://doi.org/10.3389/fphar.2021.730257.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Fan K, Cheng L, Li L. Artificial intelligence and machine learning methods in predicting anti-cancer drug combination effects. Brief Bioinform. 2021. https://doi.org/10.1093/bib/bbab271.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Plana D, Palmer AC, Sorger PK. Independent drug action in combination therapy: implications for precision oncology. Cancer Discov. 2022;12(3):606–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Yang LL, Xiao N, Liu J, et al. Differential regulation of baicalin and scutellarin on AMPK and Akt in promoting adipose cell glucose disposal. Mol Basis Dis. 2017. https://doi.org/10.1016/j.bbadis.2016.11.024.

    Article  Google Scholar 

  11. Pawana B, Dasuni WPW, Hasriadi, et al. Combination of curcumin and piperine synergistically improves pain-like behaviors in mouse models of pain with no potential CNS side effects. Chin Med. 2022. https://doi.org/10.1186/s13020-022-00660-1.

    Article  Google Scholar 

  12. Matthews DR, Paldánius PM, Proot P, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519–29.

    Article  CAS  PubMed  Google Scholar 

  13. Patridge E, Gareiss P, Kinch MS, et al. An analysis of FDA-approved drugs: natural products and their derivatives. Drug Discov Today. 2016;21(2):204–7.

    Article  CAS  PubMed  Google Scholar 

  14. Huang K, Zhang P, Zhang Z, et al. Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: efficacies and mechanisms. Pharmacol Ther. 2021;225: 107843.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Shao L. Possible relationship between traditional Chinese medicine ZHENG and molecular networks. The First Academic Annual Meeting of the China Association for Science and Technology. 1999:519.

  16. Shao L, Yongyan W, Liang J, et al. A discussion and case study of complexities in traditional Chinese medicine. J System Simul. 2002;14:1429–31.

    Google Scholar 

  17. Shao L. Framework and practice of network-based studies for Chinese herbal formula. J Chin Integr Med. 2007. https://doi.org/10.3736/jcim20070501.

    Article  Google Scholar 

  18. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008. https://doi.org/10.1038/nchembio.118.

    Article  PubMed  Google Scholar 

  19. Jiahu P. New paradigm for drug discovery based on network pharmacology. Chin J New Drugs Clin Rem. 2009;28(10):721–6.

    Google Scholar 

  20. Network LS, Syndrome SUTCM, Formula H. Network systems underlying traditional Chinese medicine syndrome and herb formula. Curr Bioinform. 2009;4(3):188–96.

    Article  Google Scholar 

  21. Shao L. Network target: a starting point for traditional Chinese medicine network pharmacology. China J Chin Materia Med. 2011;36(15):2017–20.

    Google Scholar 

  22. Societies WFoCM. Network pharmacology evaluation method guidance. World Chin Med. 2021;16(04):527–32.

    Google Scholar 

  23. Kibble M, Saarinen N, Tang J, et al. Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products. Nat Prod Rep. 2015;32(8):1249–66.

    Article  CAS  PubMed  Google Scholar 

  24. Nogales C, Mamdouh ZM, List M, et al. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci. 2022;43(2):136–50.

    Article  CAS  PubMed  Google Scholar 

  25. Lee WY, Lee CY, Kim YS, et al. The methodological trends of traditional herbal medicine employing network pharmacology. Biomolecules. 2019. https://doi.org/10.3390/biom9080362.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Liwen H, Shanjun C, Rong D, et al. Progress of network pharmacology applications in studying the complex mechanisms of action of traditional Chinese medicin. Shandong Sci. 2021;34(6):22–31.

    Google Scholar 

  27. Zhuang YS, Cai BC, Zhang ZL. Application progress of network pharmacology in traditional Chinese medicine research. J Nanjing Univ Tradit Chin Me. 2021;37(01):156–60.

    Google Scholar 

  28. Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)(1). Autophagy. 2021;17(1):1–382.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Zheng JH, Wu M, Wang HY, et al. Network pharmacology to unveil the biological basis of health-strengthening herbal medicine in cancer treatment. Cancers. 2018;10(11):23.

    Article  Google Scholar 

  30. Hu Y, Chen X, Hu M, et al. Medicinal and edible plants in the treatment of dyslipidemia: advances and prospects. Chin Med. 2022;17(1):113.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Birhan YS. Medicinal plants utilized in the management of epilepsy in Ethiopia: ethnobotany, pharmacology and phytochemistry. Chin Med. 2022;17(1):129.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Bhuia MS, Rahaman MM, Islam T, et al. Neurobiological effects of gallic acid: current perspectives. Chin Med. 2023;18(1):27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Zahra N, Iqbal J, Arif M, et al. A comprehensive review on traditional uses, phytochemistry and pharmacological properties of Paeonia emodi Wall. ex Royle: current landscape and future perspectives. Chin Med. 2023;18(1):23.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Yuan S, Wang Q, Li J, et al. Inflammatory bowel disease: an overview of Chinese herbal medicine formula-based treatment. Chin Med. 2022;17(1):74.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Wu JS, Zhang FQ, Li ZZ, et al. Integration strategy of network pharmacology in Traditional Chinese Medicine: a narrative review. J Tradit Chin Med. 2022. https://doi.org/10.19852/j.cnki.jtcm.20220408.003.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Zhang RZ, Zhu X, Bai H, et al. Network pharmacology databases for traditional Chinese medicine: review and assessment. Front Pharmacol. 2019. https://doi.org/10.3389/fphar.2019.00123.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Luo TT, Lu Y, Yan SK, et al. Network pharmacology in research of Chinese medicine formula: methodology, application and prospective. Chin J Integrative Med. 2020. https://doi.org/10.1007/s11655-019-3064-0.

    Article  Google Scholar 

  38. Wang X, Wang ZY, Zheng JH, et al. TCM network pharmacology: a new trend towards combining computational, experimental and clinical approaches. Chin J Nat Med. 2021;19(1):1–11.

    PubMed  Google Scholar 

  39. Ming N, Siqin Z, Bo Z, et al. Interpretation of network pharmacology evaluation method Guidance. Chin Tradit Herbal Drugs. 2021;52(14):4119–29.

    Google Scholar 

  40. Zhang RZ, Zhu X, Bai H, et al. Network pharmacology databases for traditional Chinese Medicine: review and assessment. Front Pharmacol. 2019;10:14.

    CAS  Google Scholar 

  41. Ru JL, Li P, Wang JN, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6:6.

    Article  Google Scholar 

  42. Fang SS, Dong L, Liu L, et al. HERB: a high-throughput experiment- and reference-guided database of traditional Chinese medicine. Nucleic acids Res. 2020. https://doi.org/10.1093/nar/gkaa1063.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Lv QJ, Chen GX, He HH, et al. TCMBank-the largest TCM database provides deep learning-based Chinese-Western medicine exclusion prediction. Signal Transduc Targeted Ther. 2023. https://doi.org/10.1038/s41392-023-01339-1.

    Article  Google Scholar 

  44. Hao Y, Li Y, Hong K, et al. HIT: linking herbal active ingredients to targets. Nucleic Acids Res. 2011. https://doi.org/10.1093/nar/gkq1165.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Xu HY, Zhang YQ, Liu ZM, et al. ETCM: an encyclopaedia of traditional Chinese medicine. Nucleic Acids Res. 2019;47(D1):D976–82.

    Article  CAS  PubMed  Google Scholar 

  46. Huang L, Xie DL, Yu YR, et al. TCMID 2.0: a comprehensive resource for TCM. Nucleic Acids Res. 2018. https://doi.org/10.1093/nar/gkx1028.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Xian Z, Peng Z, Yali W, et al. CMAUP: a database of collective molecular activities of useful plants. Nucleic Acids Res. 2019. https://doi.org/10.1093/nar/gky965.

    Article  Google Scholar 

  48. Li B, Ma C, Zhao X, et al. YaTCM: Yet another traditional chinese medicine database for drug discovery. Comput Structural Biotechnol J. 2018. https://doi.org/10.1016/j.csbj.2018.11.002.

    Article  Google Scholar 

  49. Chen CYC. TCM Database@Taiwan: the world’s largest traditional Chinese medicine database for drug screening In Silico. PLoS ONE. 2011;6(1):5.

    Article  Google Scholar 

  50. Kim S, Chen J, Cheng TJ, et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2021;49(D1):D1388–95.

    Article  CAS  PubMed  Google Scholar 

  51. Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021. https://doi.org/10.1093/nar/gkaa1074.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Bateman A, Martin MJ, Orchard S, et al. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res. 2021;49(D1):D480–9.

    Article  Google Scholar 

  53. Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018. https://doi.org/10.1093/nar/gkx1037.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Amberger JS, Bocchini CA, Schiettecatte F, et al. OMIM.org: Online Mendelian Inheritance in Man (OMIM (R)), an online catalog of human genes and genetic disorders. Nucleic Acids Res. 2015. https://doi.org/10.1093/nar/gku1205.

    Article  PubMed  Google Scholar 

  55. Stelzer G, Rosen N, Plaschkes I, et al. The genecards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinform. 2016. https://doi.org/10.1002/cpbi.5.

    Article  Google Scholar 

  56. Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020. https://doi.org/10.1093/nar/gkz1021.

    Article  PubMed  Google Scholar 

  57. Zhou Y, Zhang Y, Lian X, et al. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Res. 2022. https://doi.org/10.1093/nar/gkab953.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Sherman BT, Hao M, Qiu J, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50(W1):W216–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Minoru K, Miho F, Yoko S, et al. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2020. https://doi.org/10.1093/nar/gkaa970.

    Article  Google Scholar 

  61. Zhang GB, Li QY, Chen QL, et al. Network pharmacology: a new approach for chinese herbal medicine research. Evidence-Based Compl Alternat Med. 2013;2013: 621423.

    Google Scholar 

  62. Wu L, Wang Y, Fan X. Tools for network pharmacology study: network visualization and network analysis. China J Chin Materia Medica. 2011;36(21):2923–5.

    Google Scholar 

  63. Yang J, Tian S, Zhao J, et al. Exploring the mechanism of TCM formulae in the treatment of different types of coronary heart disease by network pharmacology and machining learning. Pharmacol Res. 2020. https://doi.org/10.1016/j.phrs.2020.105034.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Luo TT, Lu Y, Yan SK, et al. Network pharmacology in research of Chinese medicine formula: methodology, application and prospective. Chin J Integr Med. 2020;26(1):72–80.

    Article  CAS  PubMed  Google Scholar 

  65. Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med. 2013;11(2):110–20.

    Article  PubMed  Google Scholar 

  66. Fatima N, Muhammad TuQ, Ali AU, et al. Network pharmacology approach for medicinal plants review and assessment. Pharmaceuticals. 2022. https://doi.org/10.3390/ph15050572.

    Article  Google Scholar 

  67. Oskooei A, Manica M, Mathis R, et al. Network-based Biased Tree Ensembles (NetBiTE) for drug sensitivity prediction and drug sensitivity biomarker identification in cancer. Sci Rep. 2019;9:13.

    Article  Google Scholar 

  68. Zhang W, Chen Y, Jiang H, et al. Integrated strategy for accurately screening biomarkers based on metabolomics coupled with network pharmacology. Talanta. 2020. https://doi.org/10.1016/j.talanta.2020.120710.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Fang SQ, Liu YH, Zhao KP, et al. Transcriptional profiling and network pharmacology analysis identify the potential biomarkers from Chinese herbal formula Huosu Yangwei Formula treated gastric cancer in vivo. Chin J Nat Med. 2021;19(12):944–53.

    CAS  PubMed  Google Scholar 

  70. Dong MY, Du HT, Li XL, et al. Discovery of biomarkers and potential mechanisms of agarwood incense smoke intervention by untargeted metabolomics and network pharmacology. Drug Des Dev Ther. 2022;16:265–78.

    Article  CAS  Google Scholar 

  71. Chen P, Zhang X, Ding R, et al. Patient-derived organoids can guide personalized-therapies for patients with advanced breast cancer. Adv Sci. 2021;8(22): e2101176.

    Article  Google Scholar 

  72. Yuan YX, Wu Q, Zhao J, et al. Investigation of pathogenesis and therapeutic targets of acute myeloid leukemia based on untargeted plasma metabolomics and network pharmacology approach. J Pharm Biomed Anal. 2021. https://doi.org/10.1016/j.jpba.2020.113824.

    Article  PubMed  Google Scholar 

  73. Sun G, Li X, Wei J, et al. Pharmacodynamic substances in Salvia miltiorrhiza for prevention and treatment of hyperlipidemia and coronary heart disease based on lipidomics technology and network pharmacology analysis. Biomed Pharmacother. 2021. https://doi.org/10.1016/j.biopha.2021.111846.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Chen Y, Li K, Zhao H, et al. Integrated lipidomics and network pharmacology analysis to reveal the mechanisms of berberine in the treatment of hyperlipidemia. J Transl Med. 2022;20(1):412.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Chen L, Zhao X, Wei S, et al. Mechanism of Paeoniflorin on ANIT-Induced cholestatic liver injury using integrated metabolomics and network pharmacology. Front Pharmacol. 2021. https://doi.org/10.3389/fphar.2021.737630.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Hao J, Hu H, Liu J, et al. Integrated metabolomics and network pharmacology study on immunoregulation mechanisms of panax ginseng through macrophages. Evidence-Based Compl Altern Med. 2019. https://doi.org/10.1155/2019/3630260.

    Article  Google Scholar 

  77. Guo Q, Niu W, Li X, et al. Study on hypoglycemic effect of the drug pair of astragalus radix and dioscoreae rhizoma in T2DM rats by network pharmacology and metabonomics. Molecules. 2019. https://doi.org/10.3390/molecules24224050.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Xu T, Wang P, Zheng X, et al. The therapeutic effects and mechanisms of Long Chai Fang on chronic hepatitis B. Ann Transl Med. 2021. https://doi.org/10.21037/atm-21-1923.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Gu J, Li L, Wang D, et al. Deciphering metabonomics biomarkers-targets interactions for psoriasis vulgaris by network pharmacology. Ann Med. 2018;50(4):323–32.

    Article  CAS  PubMed  Google Scholar 

  80. Gao Y, Xu T, Zhao YX, et al. A Novel network pharmacology strategy to decode metabolic biomarkers and targets interactions for depression. Front Psych. 2020. https://doi.org/10.3389/fpsyt.2020.00667.

    Article  Google Scholar 

  81. Ngo FY, Wang W, Chen Q, et al. Network pharmacology analysis and molecular characterization of the herbal medicine formulation Qi-Fu-Yin for the inhibition of the neuroinflammatory biomarker iNOS in microglial BV-2 cells: implication for the treatment of alzheimer’s disease. Oxid Med Cell Longev. 2020;2020:5780703.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Wu J, Liu L, Hu H, et al. Bioinformatic analysis and experimental identification of blood biomarkers for chronic nonunion. J Orthop Surg Res. 2020;15(1):208.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Poornima P, Kumar JD, Zhao QL, et al. Network pharmacology of cancer: from understanding of complex interactomes to the design of multi-target specific therapeutics from nature. Pharmacol Res. 2016;111:290–302.

    Article  CAS  PubMed  Google Scholar 

  84. Guo XY, Yu X, Zheng BQ, et al. Network pharmacology-based identification of potential targets of lonicerae japonicae flos acting on anti-inflammatory effects. Biomed Res Int. 2021;2021:18.

    Article  Google Scholar 

  85. El-Banna AA, Darwish RS, Ghareeb DA, et al. Metabolic profiling of Lantana camara L. using UPLC-MS/MS and revealing its inflammation-related targets using network pharmacology-based and molecular docking analyses. Sci Rep. 2022;12(1):14828.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Yang L, Chen X, Oi Lam Ung C, et al. Clinical and economic evaluation of salvianolate injection for coronary heart disease: a retrospective study based on national health insurance data in China. Front Pharmacol. 2020;11:887.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Tao QY, Du JX, Li XT, et al. Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19. Drug Dev Ind Pharm. 2020;46(8):1345–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Chu XD, Zhang YR, Lin ZB, et al. A network pharmacology approach for investigating the multi-target mechanisms of Huangqi in the treatment of colorectal cancer. Transl Cancer Res. 2021;10(2):681–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Huang S, Zhang Z, Li W, et al. Network pharmacology-based prediction and verification of the active ingredients and potential targets of zuojinwan for treating colorectal cancer. Drug Des Dev Ther. 2020;14:2725–40.

    Article  CAS  Google Scholar 

  90. Jiang L, Shi Z, Yang Y. Network pharmacology-based approach to investigate the molecular targets of rhubarb for treating cancer. Evidence-Based Compl Altern Med. 2021. https://doi.org/10.1155/2021/9945633.

    Article  Google Scholar 

  91. Deng Z, Chen G, Shi Y, et al. Curcumin and its nano-formulations: defining triple-negative breast cancer targets through network pharmacology, molecular docking, and experimental verification. Front Pharmacol. 2022. https://doi.org/10.3389/fphar.2022.920514.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Cui Q, Hu Y, Ma D, et al. Reserarch on the key anti-gastric cancer targets andregulatory networks of volatile oil constituents of ginseng based on network pharmacology. Acta Medica Mediterranea. 2022;38(3):1509–14.

    Google Scholar 

  93. Gong YB, Fu SJ, Wei ZR, et al. Predictive study of the active ingredients and potential targets of codonopsis pilosula for the treatment of osteosarcoma via network pharmacology. Evidence-Based Compl Altern Med. 2021. https://doi.org/10.1155/2021/1480925.

    Article  Google Scholar 

  94. Aisa Y, Yunusi K, Chen Q, et al. Systematic understanding of the potential targets and pharmacological mechanisms of acteoside by network pharmacology approach. Med Chem Res. 2020;29(4):793–801.

    Article  CAS  Google Scholar 

  95. Cai X, Zhang H, Li T. Multi-target pharmacological mechanisms of Salvia miltiorrhiza against oral submucous fibrosis: a network pharmacology approach. Arch Oral Biol. 2021. https://doi.org/10.1016/j.archoralbio.2021.105131.

    Article  PubMed  Google Scholar 

  96. Cai X, Xu X. Investigation of the key targets and pharmacological mechanisms of rhamnocitrin against oxaliplatin-induced neuropathic pain based on network pharmacology approach and experimental validation. Gen Physiol Biophys. 2022;41(3):191–203.

    Article  CAS  PubMed  Google Scholar 

  97. Cui XY, Wu X, Lu D, et al. Network pharmacology-based strategy for predicting therapy targets of Sanqi and Huangjing in diabetes mellitus. World J Clin Cases. 2022;10(20):6900–14.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Dong Y, Zhao Q, Wang Y. Network pharmacology-based investigation of potential targets of astragalus membranaceous-angelica sinensis compound acting on diabetic nephropathy. Sci Rep. 2021. https://doi.org/10.1038/s41598-021-98925-6.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Fu S, Zhou Y, Hu C, et al. Network pharmacology and molecular docking technology-based predictive study of the active ingredients and potential targets of rhubarb for the treatment of diabetic nephropathy. BMC Complement Med Ther. 2022;22(1):210.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. He D, Huang JH, Zhang ZY, et al. A Network pharmacology-based strategy for predicting active ingredients and potential targets of LiuWei DiHuang Pill in treating type 2 diabetes mellitus. Drug Des Dev Ther. 2020;14:949.

    Article  Google Scholar 

  101. Chen D, Wu Y, Chen Y, et al. Exploration of the molecular targets and mechanisms of suxiao xintong dropping pills for myocardial infarction by network pharmacology method. 2021. Biosci Rep. https://doi.org/10.1042/BSR20204211.

  102. Cheng J, Zhang M, Zheng Y, et al. Integrative analysis of network pharmacology and proteomics to identify key targets of Tuomin-Zhiti-Decoction for allergic rhinitis. J Ethnopharmacol. 2022. https://doi.org/10.1016/j.jep.2022.115448.

    Article  PubMed  Google Scholar 

  103. Fang Y, Liu J, Xin L, et al. Exploration of the immuno-inflammatory potential targets of xinfeng capsule in patients with ankylosing spondylitis based on data mining, network pharmacology, and molecular docking. Evidence-Based Compl Altern Med. 2022;2022:5382607.

    Google Scholar 

  104. Haojia W, Zhishan W, Xiaotian F, et al. Identification of key pharmacological components and targets for Aidi injection in the treatment of pancreatic cancer by UPLC-MS, network pharmacology, and in vivo experiments. Chinese Med. 2023. https://doi.org/10.1186/s13020-023-00710-2.

    Article  Google Scholar 

  105. He B, Chen Z, Nie Y, et al. Exploring and verifying the mechanism and targets of shenqi pill in the treatment of nonalcoholic steatohepatitis via network pharmacology and experiments. J Immunol Res. 2022;2022:6588144.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Hong W, Li S, Wu L, et al. Prediction of VEGF-C as a key target of pure total flavonoids from citrus against NAFLD in Mice via network pharmacology. Front Pharmacol. 2019. https://doi.org/10.3389/fphar.2019.00582.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Hong M, Li S, Wang N, et al. A Biomedical Investigation of the Hepatoprotective effect of Radix salviae miltiorrhizae and Network pharmacology-based prediction of the active compounds and molecular targets. Int J Mol Sci. 2017. https://doi.org/10.3390/ijms18030620.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Yanfen C, Meng X, Jiamei C, et al. Quality assessment and Q-markers discovery of Tongsaimai tablet by integrating serum pharmacochemistry and network pharmacology for anti-atherosclerosis benefit. Chin Med. 2022. https://doi.org/10.1186/s13020-022-00658-9.

    Article  Google Scholar 

  109. Oh KK, Adnan M, Cho DH. Network pharmacology of bioactives from Sorghum bicolor with targets related to diabetes mellitus. PLoS ONE. 2020;15(12):24.

    Article  Google Scholar 

  110. Zhang MM, Wang D, Lu F, et al. Identification of the active substances and mechanisms of ginger for the treatment of colon cancer based on network pharmacology and molecular docking. BioData Min. 2021;14(1):16.

    Article  Google Scholar 

  111. Cheung MK, Yue GG, Gomes AJ, et al. Network pharmacology reveals potential functional components and underlying molecular mechanisms of Andrographis paniculata in esophageal cancer treatment. Phytother Res. 2022;36(4):1748–60.

    Article  CAS  PubMed  Google Scholar 

  112. Han L, Han Y. Network pharmacology-based study on the active component and mechanism of the anti-gastric-cancer effect of herba sarcandrae. J Healthcare Eng. 2021. https://doi.org/10.1155/2021/3001131.

    Article  Google Scholar 

  113. Han DE, Yue ZS, Li HW, et al. Anti-depressant components and mechanism of Rehmanniae Radix based on UPLC-Q-Orbitrap HRMS and network pharmacology. China J Chin Materia Medic. 2022;47(4):1051–63.

    Google Scholar 

  114. Bao YT, Wang Y, Ren XD, et al. Exploration on antibacterial activity and mechanism of flowers and leaves from Paeonia rockii based on network pharmacology. China J Chin Materia Medica. 2018;43(4):779–85.

    Google Scholar 

  115. Bi J, Lin Y, Sun Y, et al. Investigation of the active ingredients and mechanism of polygonum cuspidatum in asthma based on network pharmacology and experimental verification. Drug Des Dev Ther. 2021;15:1075–89.

    Article  Google Scholar 

  116. Ming Z, Guoyan R, Bin Z, et al. Screening and identification of a novel antidiabetic peptide from collagen hydrolysates of Chinese giant salamander skin: network pharmacology, inhibition kinetics and protection of IR-HepG2 cells. Food Funct. 2022;13(6):3329–42.

    Article  Google Scholar 

  117. Dang Y, Meng-Hua J, Chen-Zi LI, et al. Investigation of active components and mechanism of Pudilan Xiaoyan Oral Liquid based on network pharmacology. China J Chin Materia Medica. 2020;45(18):4291–8.

    Google Scholar 

  118. Fan G, Li Q, Li HJ, et al. Active ingredients and anti-arthritic mechanisms of Ba-Wei-Long-Zuan granule revealed by H-1-NMR-based metabolomics combined with network pharmacology analysis. Chem Biodiv. 2020. https://doi.org/10.1002/cbdv.202000122.

    Article  Google Scholar 

  119. Chen W, He L, Zhong L, et al. Identification of active compounds and mechanism of huangtu decoction for the treatment of ulcerative colitis by network pharmacology combined with experimental verification. Drug Des Devel Ther. 2021;15:4125–40.

    Article  PubMed  PubMed Central  Google Scholar 

  120. Wang H, Wu R, Xie D, et al. A combined phytochemistry and network pharmacology approach to reveal the effective substances and mechanisms of wei-fu-chun tablet in the treatment of precancerous lesions of gastric cancer. Front Pharmacol. 2020;11: 558471.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Li C, Zhang WY, Yu Y, et al. Discovery of the mechanisms and major bioactive compounds responsible for the protective effects of Gualou Xiebai decoction on coronary heart disease by network pharmacology analysis. Phytomedicine. 2019;56:261–8.

    Article  CAS  PubMed  Google Scholar 

  122. Dai W, Sun Y, Zhong G. A network pharmacology approach to estimate the active ingredients and potential targets of cuscutae semen in the treatment of osteoporosis. Med Sci Monit. 2020. https://doi.org/10.12659/MSM.920485.

    Article  PubMed  PubMed Central  Google Scholar 

  123. Fan L, Feng S, Wang T, et al. Chemical composition and therapeutic mechanism of Xuanbai Chengqi Decoction in the treatment of COVID-19 by network pharmacology, molecular docking and molecular dynamic analysis. Mol Diversity. 2022. https://doi.org/10.1007/s11030-022-10415-7.

    Article  Google Scholar 

  124. Bai X, Tang Y, Li Q, et al. An Integrated analysis of network pharmacology, molecular docking, and experiment validation to explore the new candidate active component and mechanism of cuscutae semen-mori fructus coupled-herbs in treating oligoasthenozoospermia. Drug Des Dev Ther. 2021;15:2059–89.

    Article  Google Scholar 

  125. Li S, Ding Q-Y. New progress of interdisciplinary research between network toxicology, quality markers and TCM network pharmacology. Chinese Herbal Medicines. 2019;11(4):347–8.

    Article  CAS  Google Scholar 

  126. Cao ZY, Liu JT, Han YQ, et al. Identification of Q-markers for Cistanches Herba based on HPLC-Q-TOF-MS/MS and network pharmacology. China J Chin Materia Medica. 2022;47(7):1790–801.

    Google Scholar 

  127. Chen L, Huang X, Wang H, et al. Integrated metabolomics and network pharmacology strategy for ascertaining the quality marker of flavonoids for Sophora flavescens. J Pharm Biomed Anal. 2020. https://doi.org/10.1016/j.jpba.2020.113297.

    Article  PubMed  PubMed Central  Google Scholar 

  128. Duan S, Niu L, Yin T, et al. A novel strategy for screening bioavailable quality markers of traditional Chinese medicine by integrating intestinal absorption and network pharmacology: Application to Wu Ji Bai Feng Pill. Phytomedicine. 2020. https://doi.org/10.1016/j.phymed.2020.153226.

    Article  PubMed  PubMed Central  Google Scholar 

  129. Li D, Lv B, Wang D, et al. Network pharmacology and bioactive equivalence assessment integrated strategy driven q-markers discovery for da-cheng-qi decoction to attenuate intestinal obstruction. Phytomedicine. 2020. https://doi.org/10.1016/j.phymed.2020.153236.

    Article  PubMed  PubMed Central  Google Scholar 

  130. Li ZT, Zhang FX, Fan CL, et al. Discovery of potential Q-marker of traditional Chinese medicine based on plant metabolomics and network pharmacology: periplocae cortex as an example. Phytomedicine. 2021. https://doi.org/10.1016/j.phymed.2021.153535.

    Article  PubMed  PubMed Central  Google Scholar 

  131. Liao M, Shang H, Li Y, et al. An integrated approach to uncover quality marker underlying the effects of Alisma orientale on lipid metabolism, using chemical analysis and network pharmacology. Phytomedicine. 2018;45:93–104.

    Article  CAS  PubMed  Google Scholar 

  132. Luo L, Gao W, Zhang Y, et al. Integrated Phytochemical Analysis Based on UPLC-MS and Network Pharmacology Approaches to Explore the Quality Control Markers for the Quality Assessment of Trifolium pratenseL. Molecules. 2020. https://doi.org/10.3390/molecules25173787.

    Article  PubMed  PubMed Central  Google Scholar 

  133. Qin LL, Yu M, Zhang HX, et al. Quality markers of Baizhu dispensing granules based on multi-component qualitative and quantitative analysis combined with network pharmacology and chemometric analysis. J Ethnopharmacol. 2022;288: 114968.

    Article  CAS  PubMed  Google Scholar 

  134. Simayi J, Abulizi A, Nuermaimaiti M, et al. UHPLC-Q-TOF-MS/MS and network pharmacology analysis to reveal quality markers of xinjiang cydonia oblonga mill for antiatherosclerosis. Biomed Res Int. 2022. https://doi.org/10.1155/2022/4176235.

    Article  PubMed  PubMed Central  Google Scholar 

  135. Lan JL, Ruan YP, Mao ZJ, et al. Q-marker prediction analysis of rhubarb in fengyin decoction based on fingerprint and network pharmacology. Natural Prod Commun. 2021. https://doi.org/10.1177/1934578X211038792.

    Article  Google Scholar 

  136. Wang T, Lin S, Li H, et al. A stepwise integrated multi-system to screen quality markers of Chinese classic prescription Qingzao Jiufei decoction on the treatment of acute lung injury by combining “network pharmacology-metabolomics-PK/PD modeling.” Phytomedicine. 2020. https://doi.org/10.1016/j.phymed.2020.153313.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Deng JL, Ma Y, He YQ, et al. A network pharmacology-based investigation to the pharmacodynamic material basis and mechanisms of the anti-inflammatory and anti-viral effect of isatis indigotica. Drug Des Dev Ther. 2021;15:3193–206.

    Article  Google Scholar 

  138. Cui S, Chen S, Wu Q, et al. A network pharmacology approach to investigate the anti-inflammatory mechanism of effective ingredients from Salvia miltiorrhiza. Int Immunopharmacol. 2020. https://doi.org/10.1016/j.intimp.2019.106040.

    Article  PubMed  PubMed Central  Google Scholar 

  139. Yang L, Luo H, Tan D, et al. A recent update on the use of Chinese medicine in the treatment of inflammatory bowel disease. Phytomedicine. 2021;92: 153709.

    Article  CAS  PubMed  Google Scholar 

  140. An W, Huang Y, Chen S, et al. Mechanisms of Rhizoma Coptidis against type 2 diabetes mellitus explored by network pharmacology combined with molecular docking and experimental validation. Sci Rep. 2021;11(1):20849.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. Deng X, Liang Y, Hu J, et al. Studies on the mechanism of Gegen Qinlian Decoction in treating diabetes mellitus based on network pharmacology. Nat Prod Commun. 2021. https://doi.org/10.1177/1934578X20982138.

    Article  Google Scholar 

  142. Duan H, Zhang Q, Liu J, et al. An Integrated approach based on network pharmacology combined with experimental verification reveals AMPK/PI3K/Akt signaling is an important way for the anti-type 2 diabetic activity of silkworm excrement. Diabetes Metab Syndrome Obesity-Targets Ther. 2021;14:601–16.

    Article  Google Scholar 

  143. Duan Y, Zhang D, Ye Y, et al. Integrated metabolomics and network pharmacology to establish the action mechanism of qingrekasen granule for treating nephrotic syndrome. Front Pharmacol. 2021. https://doi.org/10.3389/fphar.2021.765563.

    Article  PubMed  PubMed Central  Google Scholar 

  144. Fang J, Wang C, Zheng J, et al. Network pharmacology study of Yishen capsules in the treatment of diabetic nephropathy. PLoS ONE. 2022;17(9):e0273498.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Guo W, Huang JH, Wang N, et al. Integrating network pharmacology and pharmacological evaluation for deciphering the action mechanism of herbal formula zuojin pill in suppressing hepatocellular carcinoma. Front Pharmacol. 2019;10:21.

    Article  Google Scholar 

  146. Cui Q, Ma YH, Yu HY, et al. Systematic analysis of the mechanism of hydroxysafflor yellow A for treating ischemic stroke based on network pharmacology technology. Eur J Pharmacol. 2021. https://doi.org/10.1016/j.ejphar.2021.174360.

    Article  PubMed  Google Scholar 

  147. Dong R, Huang R, Shi X, et al. Exploration of the mechanism of luteolin against ischemic stroke based on network pharmacology, molecular docking and experimental verification. Bioengineered. 2021;12(2):12274–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  148. Jing C, Yangyang S, Xueli X, et al. Identifying the cardioprotective mechanism of Danyu Tongmai Granules against myocardial infarction by targeted metabolomics combined with network pharmacology. Phytomedicine. 2022. https://doi.org/10.1016/j.phymed.2021.153829.

    Article  PubMed  Google Scholar 

  149. Cui QK, Li H, Li Z, et al. Study on the mechanism of the Modified Ginseng-Schisandra Decoction (MGSD) in the treatment of recurrent respiratory tract infection (RRTI) based on network pharmacology. Transl Pediatr. 2021;10(6):1701–11.

    Article  PubMed  PubMed Central  Google Scholar 

  150. Xu H, Xu SC, Li LY, et al. Integrated metabolomics, network pharmacology and biological verification to reveal the mechanisms of Nauclea officinalis treatment of LPS-induced acute lung injury. Chinese Med. 2022. https://doi.org/10.1186/s13020-022-00685-6.

    Article  PubMed  Google Scholar 

  151. Fan X, Guo X, Li Y, et al. Utilizing network pharmacology to explore the possible mechanism of coptidis rhizoma in kawasaki disease. Front Pediatr. 2021. https://doi.org/10.3389/fped.2021.708553.

    Article  PubMed  PubMed Central  Google Scholar 

  152. Gong P, Wang D, Cui D, et al. Anti-aging function and molecular mechanism of Radix Astragali and Radix Astragali preparata via network pharmacology and PI3K/Akt signaling pathway. Phytomedicine. 2021. https://doi.org/10.1016/j.phymed.2021.153509.

    Article  PubMed  Google Scholar 

  153. Lai J, Jiang F, Zhuo X, et al. Effects of Shenling Baizhu powder on pyrotinib-induced diarrhea: analysis of gut microbiota, metabonomics, and network pharmacology. Chin Med. 2022;17(1):140.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. Fu L, Wu Z, Chu Y, et al. Explore the mechanism of astragalus mongholicus bunge against nonalcoholic fatty liver disease based on network pharmacology and experimental verification. Gastroenterol Res Pract. 2022;2022:4745042.

    Article  PubMed  PubMed Central  Google Scholar 

  155. Gan XX, Zhong LK, Shen F, et al. Network pharmacology to explore the molecular mechanisms of prunella vulgaris for treating hashimoto’s thyroiditis. Front Pharmacol. 2021;12: 700896.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  156. Du X, Li C, Zhang S, et al. Exploring the pharmacological mechanism of calculus bovis in cerebral ischaemic stroke using a network pharmacology approach. J Ethnopharmacol. 2022;284: 114507.

    Article  CAS  PubMed  Google Scholar 

  157. Chen GY, Luo J, Liu Y, et al. Network pharmacology analysis and experimental validation to investigate the mechanism of total flavonoids of rhizoma drynariae in treating rheumatoid arthritis. Drug Des Dev Ther. 2022;16:1743–66.

    Article  Google Scholar 

  158. Chen DT, Shen X, Li YM, et al. Based on the Network Pharmacology Platform and Molecular Docking, to Explore the Mechanism of "Fuzi-Guizhi" in the Treatment of Osteoarthritis. Combinatorial chemistry & high throughput screening. 2022.

  159. Chen PY, Wang C, Zhang Y, et al. Predicting the molecular mechanism of “Angong Niuhuang Pills” in the treatment of COVID-19 based on network pharmacology. Natural Product Commun. 2021. https://doi.org/10.1177/1934578X211024032.

    Article  Google Scholar 

  160. Fei C, Ji D, Tong H, et al. Therapeutic mechanism of Curcuma aromatica Salisb rhizome against coronary heart disease based on integrated network pharmacology, pharmacological evaluation and lipidomics. Front Pharmacol. 2022. https://doi.org/10.3389/fphar.2022.950749.

    Article  PubMed  PubMed Central  Google Scholar 

  161. Du K, Wang WD, Han B, et al. Mechanism and experimental verification of “Polygoni Cuspidati Rhizoma et Radix-Ligustri Lucidi Fructus” combination in treatment of acute gouty arthritis based on network pharmacology. China J Chin Materia Medica. 2022;47(6):1677–86.

    Google Scholar 

  162. Wei Y, Ren S, Wang R, et al. Based on network pharmacology to explore the potential bioactive compounds and mechanisms of Zuojin Pill for the treatment of ulcerative colitis. Evidence-based complementary and alternative medicine: eCAM. 2021;2021:7567025.

    Article  PubMed  Google Scholar 

  163. Lai JJ, Jiang FX, Zhou XL, et al. Effects of Shenling Baizhu powder on pyrotinib-induced diarrhea: analysis of gut microbiota, metabonomics, and network pharmacology. Chin Med. 2022;17(1):140.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. Ye QL, Zhang Y, Yan DH, et al. Integrating pharmacokinetics and network analysis to investigate the mechanism of Moutan Cortex in blood-heat and blood stasis syndrome. Chin Med. 2022. https://doi.org/10.1186/s13020-022-00657-w.

    Article  PubMed  PubMed Central  Google Scholar 

  165. Jun SZ, Bo FY, Ling HJ, et al. Integrating network pharmacology, UPLC-Q–TOF–MS and molecular docking to investigate the effect and mechanism of Chuanxiong Renshen decoction against Alzheimer’s disease. Chinese Med. 2022. https://doi.org/10.1186/s13020-022-00698-1.

    Article  Google Scholar 

  166. Kanmin M, Hongjuan L, Xin C, et al. Hawthorn or semen cassiae-alleviated high-fat diet-induced hepatic steatosis in rats via the reduction of endoplasmic reticulum stress. Food & function. 2022.

  167. Noor F, Tahir Ul Qamar M, Ashfaq UA, et al. Network pharmacology approach for medicinal plants: review and assessment. Pharmaceuticals. 2022. https://doi.org/10.3390/ph15050572.

    Article  PubMed  PubMed Central  Google Scholar 

  168. Wu G, Zhao J, Zhao J, et al. Exploring biological basis of Syndrome differentiation in coronary heart disease patients with two distinct Syndromes by integrated multi-omics and network pharmacology strategy. Chin Med. 2021;16(1):109.

    Article  PubMed  PubMed Central  Google Scholar 

  169. Li R, Wu K, Li Y, et al. Integrative pharmacological mechanism of vitamin C combined with glycyrrhizic acid against COVID-19: findings of bioinformatics analyses. Brief Bioinform. 2021;22(2):1161–74.

    Article  CAS  PubMed  Google Scholar 

  170. Yang L, Cao J, Wei J, et al. Antiproliferative activity of berberine in HepG2 cells via inducing apoptosis and arresting cell cycle. Food Funct. 2021;12(23):12115–26.

    Article  CAS  PubMed  Google Scholar 

  171. Wang H, Zhang J, Lu Z, et al. Identification of potential therapeutic targets and mechanisms of COVID-19 through network analysis and screening of chemicals and herbal ingredients. Briefings Bioinform. 2022. https://doi.org/10.1093/bib/bbab373.

    Article  Google Scholar 

  172. Rui Z, Hongcai S, Yanwei X, et al. The development of the concept of evidence-based precision medicine use in Chinese medicine. Proceedings of the 3rd Chinese Traditional Medicine and Ethnic Medicine Information Conference. 2016:262–5.

  173. Ziyi W, Xin W, Daiyan Z, et al. Traditional Chinese medicine network pharmacology: development in new era under guidance of network pharmacology evaluation method guidance. China J Chin Materia Med. 2022;47(01):7–17.

    Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This work was financially supported by the Open Research Fund of Chengdu University of Traditional Chinese Medicine State Key Laboratory of Southwestern Chinese Medicine Resources(2018GZ2011002, SKLTCM2022013), the Key R&D Projects of Sichuan Science and Technology Department [2020YFS0463], the Science and Technology Research Project of Sichuan Administration of traditional Chinese Medicine [2021MS115], Central Nervous System Drug Key Laboratory of Sichuan Province(230016-01SZ), and National Natural Science Foundation of China (82204588).

Author information

Authors and Affiliations

Authors

Contributions

Conceptualization, methodology, and software, LL; writing-reviewing and editing, YL; data curation and writing-original draft preparation, YL, and HC; writing-reviewing and validation, LP; software and validation, HY; visualization and investigation, CL; methodology and investigation, DQ; validation and supervision, ZH; visualization and supervision, CS. All authors contributed to the article and approved the submitted version.

Corresponding authors

Correspondence to Ling Li or Peng Li.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, L., Yang, L., Yang, L. et al. Network pharmacology: a bright guiding light on the way to explore the personalized precise medication of traditional Chinese medicine. Chin Med 18, 146 (2023). https://doi.org/10.1186/s13020-023-00853-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13020-023-00853-2

Keywords